Chemistry:Senicapoc
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
2,2-Bis(4-fluorophenyl)-2-phenylacetamide | |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C20H15F2NO | |
| Molar mass | 323.34 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Senicapoc (ICA-17043) is a Gardos channel blocker.[1][2]
It has been proposed for use in sickle cell anemia.[3] Gardos channel blockers may work in the treatment of sickle cell anemia by blocking the efflux of potassium and water from red blood cells, thereby preventing the dehydration of red blood cells and stopping the polymerization of HbS.
The Gardos channel has been identified as KCNN4.[4]
The "ICA" is for Icagen, which is developing the drug.[5]
References
- ↑ "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood 111 (8): 3991–7. April 2008. doi:10.1182/blood-2007-08-110098. PMID 18192510. http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=18192510.
- ↑ "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. February 2008. doi:10.1021/jm070663s. PMID 18232633.
- ↑ Ataga KI; Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs 18 (2): 231–9. doi:10.1517/13543780802708011. PMID 19236269.
- ↑ Hoffman JF; Joiner W; Nehrke K; Potapova O; Foye K; Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. doi:10.1073/pnas.1232342100. PMID 12773623. Bibcode: 2003PNAS..100.7366H.
- ↑ "Icagen - Press Release". http://ir.icagen.com/phoenix.zhtml?c=178443&p=irol-newsArticle&ID=1207330&highlight=. Retrieved 2008-12-22.
 |  |
